General Information of Drug (ID: DMVZ57G)

Drug Name
MD1003 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMVZ57G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [2]
Triptolide DMCMDVR Autoimmune diabetes 5A10 Phase 3 [3]
Laquinimod DM3IWS8 Lupus 4A40 Phase 3 [4]
Edasalonexent DMYVBF6 Duchenne dystrophy 8C70 Phase 3 [1]
Vadimezan DMK7CYX Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
CAT 1004 DMQBP7R Duchenne dystrophy 8C70 Phase 2 [6]
Parthenolide DMCQBFT N. A. N. A. Phase 2 [7]
Recoflavone DMCSR8I Inflammatory bowel disease DD72 Phase 2 [8]
CZEN-002 DMUDMHA Fungal infection 1F29-1F2F Phase 2 [9]
XP-23829 DMELUYN Multiple sclerosis 8A40 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nuclear factor NF-kappa-B (NFKB) TTSXVID NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
3 Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
4 Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
5 Auckland Cancer Society Research Centre report
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
8 DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
9 US patent application no. US20100278784 A1.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491)